Beyond Symptom Relief: A $115M Bet on a New Future for COPD Patients

SAN FRANCISCO, CA – August 05, 2026

A defining milestone was reached this week in the protracted battle against one of the world’s most debilitating diseases. San Francisco-based Expedition Therapeutics announced the dual achievement of closing an oversubscribed $115 million Series B financing and dosing the first patient in a global Phase 2 trial for its novel chronic obstructive pulmonary disease (COPD) therapy. This convergence of significant capital and clinical progress signals more than just a corporate victory; it represents a powerful vote of confidence in a new strategy to move beyond mere symptom management and target the underlying drivers of a disease that affects hundreds of millions worldwide.

A New Strategy for an Old Foe

COPD is a relentless, progressive condition, ranking as a leading cause of death globally. For those living with it, life is often defined by a constant struggle for breath, chronic coughing, and a high risk of life-threatening exacerbations. For decades, the therapeutic arsenal has been dominated by bronchodilators and inhaled corticosteroids. While these drugs are essential for opening airways and reducing inflammation, they primarily manage symptoms. They do not halt the inexorable decline in lung function or address the root inflammatory processes for every patient.

A critical gap in care exists for the nearly 70% of COPD patients whose disease is driven by neutrophilic inflammation. This form of inflammation, characterized by an overabundance of neutrophil white blood cells, is notoriously resistant to corticosteroids and is a primary cause of the lung tissue damage that defines COPD. Expedition’s lead candidate, EXPD-101, is designed to confront this challenge head-on. It is a next-generation oral inhibitor of an enzyme called dipeptidyl peptidase 1 (DPP1).

By targeting DPP1, EXPD-101 works upstream in the inflammatory cascade. DPP1 is a crucial activator of several neutrophil serine proteases—enzymes that, when overactive, wreak havoc on lung tissue. By inhibiting DPP1, the therapy aims to quell this destructive activity at its source, offering a fundamentally different approach to treatment. “COPD remains one of the leading causes of death worldwide, yet current therapies primarily manage symptoms and do not adequately address the chronic neutrophilic inflammation that drives disease progression and exacerbations,” said James Chalmers, M.D., Ph.D., of the University of Oxford. “By selectively targeting DPP1, this investigational therapy has the potential to interrupt a key upstream inflammatory pathway, offering a novel approach that could improve outcomes for patients.”

The Financial Fuel for a Long Expedition

Developing such a novel therapy requires immense resources, and Expedition Therapeutics has secured a formidable war chest. The $115 million Series B round was not just successful; it was oversubscribed, indicating that demand from investors exceeded the shares available. The round was led by General Atlantic, a heavyweight global investor, and saw participation from a syndicate of premier life sciences backers, including RA Capital, Vivo Capital, and a long list of returning investors like Novo Holdings and Sanofi Ventures. This infusion brings the company’s total funding to nearly $300 million, providing a long runway to advance its clinical programs.

“Today marks a defining milestone for Expedition as we complete an oversubscribed Series B financing and dose the first patient in our global Phase 2 COPD clinical trial,” said Yi Larson, Founder and CEO of Expedition Therapeutics. “This financing brings together a top-tier investor syndicate who share our conviction in the potential of our science and our mission to develop differentiated therapies for patients living with serious chronic diseases.”

The composition of the investor syndicate is as important as the dollar amount. The involvement of specialist firms like RA Capital and Vivo Capital, known for their deep scientific diligence, serves as a powerful external validation of Expedition’s approach. For General Atlantic, a firm renowned for backing high-growth companies, leading this round signals a strong belief in both the science and the company's potential to scale and create a new market standard.

“Expedition is taking a differentiated scientific approach to addressing significant unmet need in inflammatory and respiratory disease,” commented Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, who will join the company’s Board of Directors. “The company's transition into Phase 2 marks an important inflection point, and we are excited to support Yi and the Expedition team as they advance EXPD-101 through clinical development.”

Navigating a Crowded but Hopeful Landscape

The path for DPP1 inhibitors has been one of both promise and caution. The mechanism is not entirely uncharted territory. Another DPP1 inhibitor, brensocatib, gained approval for treating bronchiectasis, a different chronic lung disease, validating that targeting this enzyme can be clinically effective. However, the same drug failed to meet its goals in trials for other inflammatory conditions, highlighting the complexities of the underlying biology and the need for precision.

This is where Expedition’s positioning of EXPD-101 as a “next-generation” therapy becomes critical. The company suggests its candidate has been engineered for superior potency and safety, with clean pharmacokinetics supporting a convenient once-daily oral dose. Critically, Expedition is the first company to advance a DPP1 inhibitor into a global, randomized Phase 2 trial specifically for COPD. This is a bold and strategic move, aiming to generate robust data in the largest potential patient population for this mechanism of action. By focusing on the significant neutrophilic-driven segment of COPD, the company is targeting a clear and substantial unmet need where other recent innovations, such as biologics for eosinophilic (Type 2) inflammation, do not apply.

The Patient at the Center of the Quest

Beyond the science and the financials, the true measure of this endeavor lies in its potential impact on human lives. For millions, a COPD diagnosis initiates a slow retreat from the world, as simple activities like climbing stairs or walking the dog become monumental challenges. The fear of the next exacerbation—a sudden worsening of symptoms that can lead to hospitalization—casts a long shadow over daily life. A therapy that could do more than just ease the daily symptoms, one that could potentially slow the disease’s progression and reduce these devastating exacerbations, would be transformative.

This is the ultimate “why” behind the institutional innovation and investment flowing into companies like Expedition Therapeutics. It is an acknowledgment that our shared wellbeing is intrinsically linked to our ability to tackle the chronic diseases that diminish quality of life for so many. The $115 million investment is not merely a transaction; it is an allocation of capital toward hope—the hope that a small molecule in a clinical trial today could become the breath of fresh air that patients have been waiting for.